{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:03:27Z","timestamp":1777982607254,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100022748","name":"Universidade Fernando Pessoa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022748","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11508-4","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:19:26Z","timestamp":1770207566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of genetic variants of the IGF-1 axis on surgical outcomes and prognosis in ovarian cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"In\u00eas","family":"de Almeida Lopes","sequence":"first","affiliation":[]},{"given":"Mariana","family":"Moreira Pires","sequence":"additional","affiliation":[]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Val\u00e9ria","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Guerra de Melo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"11508_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12905-025-03987-7","volume":"25","author":"X Li","year":"2025","unstructured":"Li X, Sun B, Huang X (2025) Trends and projections of global gynaecological cancer burden: age-period-cohort insights from global burden of disease 2021. BMC Womens Health 25(1):502","journal-title":"BMC Womens Health"},{"issue":"1","key":"11508_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"11508_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/ijgc-2019-000983","volume":"31","author":"F Reid","year":"2021","unstructured":"Reid F, Bhatla N, Oza AM, Blank SV, Cohen R, Adams T, Benites A, Gardiner D, Gregory S, Suzuki M, Jones A (2021) The world ovarian cancer coalition every woman study: identifying challenges and opportunities to improve survival and quality of life. Int J Gynecol Cancer 31(2):238\u2013244","journal-title":"Int J Gynecol Cancer"},{"issue":"1Suppl 1","key":"11508_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M (2021) Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet 155(1Suppl 1):61\u201385","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"11508_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/ijms25031845","volume":"25","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, R (2024) Medeiros, paradigm shift: A comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci 25(3):1845","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11508_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40944-025-00964-8","volume":"23","author":"A Giro","year":"2025","unstructured":"Giro A, Herrmann T, Bauer A, Pinard C, Godiveau M, Passildas J, Abrial C (2025) Durando, predictive and prognostic factors in epithelial ovarian cancer: A review. Indian J Gynecologic Oncol 23(1):45","journal-title":"Indian J Gynecologic Oncol"},{"key":"11508_CR7","doi-asserted-by":"publisher","first-page":"102983","DOI":"10.1016\/j.eclinm.2024.102983","volume":"79","author":"YF Wei","year":"2025","unstructured":"Wei YF, Ning L, Xu YL, Ma J, Li DR, Feng ZF, Liu FH, Li YZ, Xu HL, Li P, Yu YP, Huang DH, Li XY, Gao S, Lin CQ, Gong TT, Wu QJ, Lang JH (2025) Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017. EClinicalMedicine 79:102983","journal-title":"EClinicalMedicine"},{"key":"11508_CR8","doi-asserted-by":"publisher","first-page":"1339936","DOI":"10.3389\/fddev.2024.1339936","volume":"4","author":"W Rajapaksha","year":"2024","unstructured":"Rajapaksha W, Khetan R, Johnson IRD, Blencowe A, Garg S, Albrecht H, Gillam TA (2024) Future theranostic strategies: emerging ovarian cancer biomarkers to Bridge the gap between diagnosis and treatment. Front Drug Deliv 4:1339936","journal-title":"Front Drug Deliv"},{"key":"11508_CR9","doi-asserted-by":"publisher","first-page":"1339936","DOI":"10.3389\/fddev.2024.1339936","volume":"4","author":"W Rajapaksha","year":"2024","unstructured":"Rajapaksha W, Khetan R, Johnson IR, Blencowe A, Garg S, Albrecht H, Gillam TA (2024) Future theranostic strategies: emerging ovarian cancer biomarkers to Bridge the gap between diagnosis and treatment. Front Drug Delivery 4:1339936","journal-title":"Front Drug Delivery"},{"key":"11508_CR10","doi-asserted-by":"publisher","first-page":"107327482311597","DOI":"10.1177\/10732748231159778","volume":"30","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Linghu H (2023) Survival outcomes of patients with international federation of gynecology and obstetrics stage IV ovarian cancer: cytoreduction still matters. Cancer Control 30:10732748231159778","journal-title":"Cancer Control"},{"issue":"1","key":"11508_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12905-024-02977-5","volume":"24","author":"DM Chase","year":"2024","unstructured":"Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L (2024) The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis. BMC Womens Health 24(1):179","journal-title":"BMC Womens Health"},{"issue":"2","key":"11508_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","volume":"21","author":"KK Shih","year":"2010","unstructured":"Shih KK, Chi DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21(2):75\u201380","journal-title":"J Gynecol Oncol"},{"key":"11508_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygyno.2023.10.018","volume":"179","author":"JH Kim","year":"2023","unstructured":"Kim JH, Kim SI, Park EY, Ha HI, Kim JW, Coleman RL, Bristow RE, Park SY, Fotopoulou C, Lim MC (2023) Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis. Gynecol Oncol 179:24\u201332","journal-title":"Gynecol Oncol"},{"issue":"1","key":"11508_CR14","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1097\/MJT.0000000000001584","volume":"30","author":"A Bryant","year":"2023","unstructured":"Bryant A, Johnson E, Grayling M, Hiu S, Elattar A, Gajjar K, Craig D, Vale L, Naik R (2023) Residual disease threshold after primary surgical treatment for advanced epithelial ovarian Cancer, part 1: A systematic review and network Meta-Analysis. Am J Ther 30(1):e36\u2013e55","journal-title":"Am J Ther"},{"issue":"1","key":"11508_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1102\/1470-7330.2007.0030","volume":"7","author":"C Pomel","year":"2007","unstructured":"Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K (2007) Cytoreductive surgery in ovarian cancer. Cancer Imaging 7(1):210\u2013215","journal-title":"Cancer Imaging"},{"key":"11508_CR16","unstructured":"Compton Z, Hanlon K, Compton C, Aktipis C, Maley C (2022) A Missing Hallmark of Cancer: Dysregulation of Differentiation"},{"issue":"1","key":"11508_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cell.2014.02.041","volume":"157","author":"A S\u00e1nchez Alvarado","year":"2014","unstructured":"S\u00e1nchez Alvarado A, Yamanaka S (2014) Rethinking differentiation: stem cells, regeneration, and plasticity. Cell 157(1):110\u2013119","journal-title":"Cell"},{"issue":"7","key":"11508_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2217\/bmm-2018-0311","volume":"13","author":"A Deo","year":"2019","unstructured":"Deo A, Chaudhury S, Kannan S, Rekhi B, Maheshwari A, Gupta S, Ray P (2019) IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels. Biomark Med 13(7):511\u2013521","journal-title":"Biomark Med"},{"issue":"5","key":"11508_CR19","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cancers12051336","volume":"12","author":"A Gadducci","year":"2020","unstructured":"Gadducci A, Cosio S (2020) Therapeutic approach to Low-Grade serous ovarian carcinoma: state of Art and perspectives of clinical research. Cancers (Basel) 12(5):1336","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11508_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):138","journal-title":"Mol Cancer"},{"issue":"1","key":"11508_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther 8(1):455","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"11508_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3892\/mmr.2025.13574","volume":"32","author":"D Wu","year":"2025","unstructured":"Wu D, Dong S, Zhou W (2025) Insulin\u2013like growth factor in cancer: new perspectives (Review). Mol Med Rep 32(2):209","journal-title":"Mol Med Rep"},{"issue":"66","key":"11508_CR23","doi-asserted-by":"publisher","first-page":"110635","DOI":"10.18632\/oncotarget.22372","volume":"8","author":"N Deng","year":"2017","unstructured":"Deng N, Zhou H, Fan H, Yuan Y (2017) Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 8(66):110635\u2013110649","journal-title":"Oncotarget"},{"issue":"1","key":"11508_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13058-015-0663-3","volume":"18","author":"S de Groot","year":"2016","unstructured":"de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, B\u00f6hringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR (2016) Insulin-like growth factor 1 receptor expression and IGF1R 3129G\u2009>\u2009T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Res 18(1):3","journal-title":"Breast Cancer Res"},{"issue":"3","key":"11508_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/annonc\/mdr293","volume":"23","author":"K Shitara","year":"2012","unstructured":"Shitara K, Ito S, Misawa K, Ito Y, Ito H, Hosono S, Watanabe M, Tajima K, Tanaka H, Muro K, Matsuo K (2012) Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy. Ann Oncol 23(3):659\u2013664","journal-title":"Ann Oncol"},{"issue":"51","key":"11508_CR26","doi-asserted-by":"publisher","first-page":"e13829","DOI":"10.1097\/MD.0000000000013829","volume":"97","author":"GP Xu","year":"2018","unstructured":"Xu GP, Chen WX, Xie WY, Wu LF (2018) The association between IGF1 gene 3\u2019-UTR polymorphisms and cancer risk: A Meta-analysis. Med (Baltim) 97(51):e13829","journal-title":"Med (Baltim)"},{"issue":"3","key":"11508_CR27","first-page":"1015","volume":"36","author":"I Rohr","year":"2016","unstructured":"Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, V.A.N.N. E F, Trillsch D, Cacsire-Tong R, Chekerov J, Sehouli EI, Braicu (2016) Role of IGF-I in primary ovarian Cancer - A study of the OVCAD European consortium. Anticancer Res 36(3):1015\u20131022","journal-title":"Anticancer Res"},{"issue":"2","key":"11508_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","volume":"26","author":"J Prat","year":"2015","unstructured":"Prat J (2015) FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26(2):87\u201389","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"11508_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer 21(2):419\u2013423","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"11508_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"2","key":"11508_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11010-024-05041-w","volume":"480","author":"K Taunk","year":"2025","unstructured":"Taunk K, Jajula S, Bhavsar PP, Choudhari M, Bhanuse S, Tamhankar A, Naiya T, Kalita B, Rapole S (2025) The prowess of metabolomics in cancer research: current trends, challenges and future perspectives. Mol Cell Biochem 480(2):693\u2013720","journal-title":"Mol Cell Biochem"},{"issue":"24","key":"11508_CR32","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.3390\/cancers15245710","volume":"15","author":"M Andreou","year":"2023","unstructured":"Andreou M, Kyprianidou M, Cortas C, Polycarpou I, Papamichael D, Kountourakis P, Giannakou K (2023) Prognostic factors influencing survival in ovarian cancer patients: A 10-Year retrospective study. Cancers (Basel) 15(24):5710","journal-title":"Cancers (Basel)"},{"issue":"3","key":"11508_CR33","doi-asserted-by":"publisher","first-page":"e0194993","DOI":"10.1371\/journal.pone.0194993","volume":"13","author":"LC Chang","year":"2018","unstructured":"Chang LC, Huang CF, Lai MS, Shen LJ, Wu FL, Cheng WF (2018) Prognostic factors in epithelial ovarian cancer: A population-based study. PLoS ONE 13(3):e0194993","journal-title":"PLoS ONE"},{"issue":"1","key":"11508_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","volume":"13","author":"L Wang","year":"2025","unstructured":"Wang L, Zhang Q, Wang X, Dong Z, Liu S, Wang Q, Zhang Z, Xing J (2025) Therapeutic landscape of ovarian cancer: recent advances and emerging therapies. Biomark Res 13(1):103","journal-title":"Biomark Res"},{"key":"11508_CR35","doi-asserted-by":"publisher","first-page":"1375030","DOI":"10.3389\/fcell.2024.1375030","volume":"12","author":"Z Liu","year":"2024","unstructured":"Liu Z, Yang L, Wu W, Chen Z, Xie Z, Shi D, Cai N, Zhuo S (2024) Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma. Front Cell Dev Biol 12:1375030","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"11508_CR36","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1210\/jc.2007-0887","volume":"92","author":"M Johansson","year":"2007","unstructured":"Johansson M, McKay JD, Wiklund F, Rinaldi S, Verheus M, van Gils CH, Hallmans G, B\u00e4lter K, Adami HO, Gr\u00f6nberg H, Stattin P, Kaaks R (2007) Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and Circulating IGF-I levels. J Clin Endocrinol Metab 92(12):4820\u20134826","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"11508_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13048-022-01016-x","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Wang F, Liu T, Lv N, Yuan X, Li P (2022) WISP1 induces ovarian cancer via the IGF1\/\u03b1v\u03b23\/Wnt axis. J Ovarian Res 15(1):94","journal-title":"J Ovarian Res"},{"key":"11508_CR38","doi-asserted-by":"publisher","first-page":"755341","DOI":"10.3389\/fonc.2021.755341","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Gao C, Cao F, Wu Y, Chen S, Han X, Mo J, Qiu Z, Fan W, Zhou P, Shen L (2021) Pan-Cancer analysis of IGF-1 and IGF-1R as potential prognostic biomarkers and immunotherapy targets. Front Oncol 11:755341","journal-title":"Front Oncol"},{"issue":"2","key":"11508_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/ncb0203-87","volume":"5","author":"DJ Glass","year":"2003","unstructured":"Glass DJ (2003) Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5(2):87\u201390","journal-title":"Nat Cell Biol"},{"issue":"1","key":"11508_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2044-5040-1-4","volume":"1","author":"S Schiaffino","year":"2011","unstructured":"Schiaffino S, Mammucari C (2011) Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models. Skelet Muscle 1(1):4","journal-title":"Skelet Muscle"},{"issue":"5","key":"11508_CR41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1089\/ars.2008.2161","volume":"11","author":"G Vardatsikos","year":"2009","unstructured":"Vardatsikos G, Sahu A, Srivastava AK (2009) The insulin-like growth factor family: molecular mechanisms, redox regulation, and clinical implications. Antioxid Redox Signal 11(5):1165\u20131190","journal-title":"Antioxid Redox Signal"},{"key":"11508_CR42","doi-asserted-by":"crossref","unstructured":"Lin SL, Lin CY, Lee W, Teng CF, Shyu WC, Jeng LB (2022) Mini review: molecular interpretation of the IGF\/IGF-1R axis in cancer treatment and stem Cells-Based therapy in regenerative medicine. Int J Mol Sci 23(19):11781","DOI":"10.3390\/ijms231911781"},{"key":"11508_CR43","doi-asserted-by":"crossref","unstructured":"Powell MJ, Dufault SM, Henry JE, Allison AC, Cora R, Benz CC (2019) Pregnancy Hypertension and a Commonly Inherited IGF1R Variant (rs2016347) Reduce Breast Cancer Risk by Enhancing Mammary Gland Involution, J Oncol (2019) 6018432","DOI":"10.1155\/2019\/6018432"},{"key":"11508_CR44","doi-asserted-by":"publisher","first-page":"e923853","DOI":"10.12659\/MSM.923853","volume":"26","author":"H Xie","year":"2020","unstructured":"Xie H, Mao JS, Hu WF (2020) Insulin-Like growth factor 1 (IGF1) pathway member polymorphisms are associated with risk and prognosis of chondrosarcoma. Med Sci Monit 26:e923853","journal-title":"Med Sci Monit"},{"issue":"1","key":"11508_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2011.06.016","volume":"123","author":"ER King","year":"2011","unstructured":"King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK (2011) The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123(1):13\u201318","journal-title":"Gynecol Oncol"},{"key":"11508_CR46","doi-asserted-by":"publisher","first-page":"1055589","DOI":"10.3389\/fonc.2022.1055589","volume":"12","author":"H Werner","year":"2022","unstructured":"Werner H, LeRoith D (2022) Hallmarks of cancer: the insulin-like growth factors perspective. Front Oncol 12:1055589","journal-title":"Front Oncol"},{"issue":"1","key":"11508_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.gendis.2022.03.002","volume":"10","author":"P Wang","year":"2023","unstructured":"Wang P, Mak VC, Cheung LW (2023) Drugging IGF-1R in cancer: new insights and emerging opportunities. Genes Dis 10(1):199\u2013211","journal-title":"Genes Dis"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11508-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11508-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11508-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:03:24Z","timestamp":1770210204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11508-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11508"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11508-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8327733\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed written consent according to the principles of the Helsinki Declaration was obtained from each patient before their enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent Statement"}}],"article-number":"356"}}